CCCC (C4 Therapeutics) Interest Expense : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. C4 Therapeutics's interest expense for the three months ended in Mar. 2025 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. C4 Therapeutics's Operating Income for the three months ended in Mar. 2025 was $ -29.16 Mil. C4 Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $ 0.00 Mil. GuruFocus does not calculate C4 Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

C4 Therapeutics Interest Expense Historical Data

The historical data trend for C4 Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Interest Expense Chart

C4 Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.23

-2.15

-2.22

-1.37

C4 Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

C4 Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

C4 Therapeutics (NAS:CCCC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

C4 Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-29.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $58.45 Mil.

C4 Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

GuruFocus does not calculate C4 Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. C4 Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

C4 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472

Website

https://www.c4therapeutics.com

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Executives

Scott N Boyle	officer: Chief Business Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark Mossler	officer: Chief Accounting Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno	officer: Chief Medical Officer	607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen	director	4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch	director, officer: See Remarks	C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick	officer: Chief People Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Malcolm Salter	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal	officer: Chief Medical Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel	officer: Chief Legal Officer	C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher	officer: Chief Scientific Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472